Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Sandler

Showing results (81-90 of 90) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 90 results.
The New England Journal of Medicine|September 30, 2020
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLCRoy S Herbst, Giuseppe Giaccone, Filippo de Marinis, et al.
The New England Journal of Medicine|October 4, 2018
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung CancerLeora Horn, Aaron S Mansfield, Aleksandra Szczęsna, et al.
Nature Medicine|August 8, 2018
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumabDavid R Gandara, Sarah M Paul, Marcin Kowanetz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2005
Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancerRoy S Herbst, David H Johnson, Eric Mininberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 5, 2013
A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancerMark A Socinski, Jonathan Goldman, Iman El-Hariry, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 20, 2018
Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung CancerLouis Fehrenbacher, Joachim von Pawel, Keunchil Park, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 11, 2015
Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trialAriel Lopez-Chavez, Anish Thomas, Arun Rajan, et al.
Lancet (London, England)|December 17, 2016
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trialAchim Rittmeyer, Fabrice Barlesi, Daniel Waterkamp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 14, 2017
Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH)Solange Peters, Scott Gettinger, Melissa L Johnson, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 10, 2018
Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1)Marcin Kowanetz, Wei Zou, Scott N Gettinger, et al.
Pageof 9

Showing results (81-90 of 90) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 90 results.
The New England Journal of Medicine|September 30, 2020
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLCRoy S Herbst, Giuseppe Giaccone, Filippo de Marinis, et al.
The New England Journal of Medicine|October 4, 2018
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung CancerLeora Horn, Aaron S Mansfield, Aleksandra Szczęsna, et al.
Nature Medicine|August 8, 2018
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumabDavid R Gandara, Sarah M Paul, Marcin Kowanetz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2005
Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancerRoy S Herbst, David H Johnson, Eric Mininberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 5, 2013
A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancerMark A Socinski, Jonathan Goldman, Iman El-Hariry, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 20, 2018
Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung CancerLouis Fehrenbacher, Joachim von Pawel, Keunchil Park, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 11, 2015
Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trialAriel Lopez-Chavez, Anish Thomas, Arun Rajan, et al.
Lancet (London, England)|December 17, 2016
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trialAchim Rittmeyer, Fabrice Barlesi, Daniel Waterkamp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 14, 2017
Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH)Solange Peters, Scott Gettinger, Melissa L Johnson, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 10, 2018
Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1)Marcin Kowanetz, Wei Zou, Scott N Gettinger, et al.
Pageof 9